|
title
|
type of...
|
start
|
status
|
|
| |
|
A Study to Evaluate Imetelstat (GRN163L) in...
|
clinical studies
|
2021
|
scheduled
|
|
|
A phase 3, multicenter, open-label, randomi...
|
clinical studies
|
2021
|
scheduled
|
|
|
A phase 3, multicenter, open-label, randomi...
|
clinical studies
|
2021
|
scheduled
|
|
|
Atezolizumab in combination with Bevacizuma...
|
clinical studies
|
2021
|
ongoing - rec...
|
|
|
SAKK 17/18 Origin
|
clinical studies
|
2021
|
scheduled
|
|
|
A PHASE II, OPEN-LABEL, MULTICENTER STUDY
|
clinical studies
|
2021
|
scheduled
|
|
|
Predictive markers for checkpoint-based imm...
|
fundamental r...
|
2020
|
ongoing - rec...
|
|
|
Lymphopenie bei myeloproliferativen Neoplas...
|
clinical studies
|
2020
|
ongoing - rec...
|
|
|
BMS CA209-914 (Checkmate 914)A Phase 3 Rand...
|
clinical studies
|
2020
|
ongoing - rec...
|
|
|
Trial: SAKK 66/17 Intratumoral injection of...
|
clinical studies
|
2020
|
ongoing - rec...
|
|
|
A phase II, open label, randomized, paralle...
|
clinical studies
|
2020
|
ongoing - rec...
|
|
|
A PHASE II, MULTICENTRE, OPEN-LABEL STUDY O...
|
clinical studies
|
2020
|
scheduled
|
|
|
A Randomized, Double-blind, Adaptive, Phase...
|
clinical studies
|
2020
|
ongoing - rec...
|
|
|
Protocol SAKK 11/16: Personalized and cell-...
|
clinical studies
|
2020
|
scheduled
|
|
|
A Phase I/IIA, Multi-Centre, Open-Label, Do...
|
clinical studies
|
2020
|
ongoing - rec...
|
|
|
Phase 3, Randomized, Open Label Study to Co...
|
clinical studies
|
2020
|
scheduled
|
|
|
A Phase 3, Randomized, Double-blind Trial o...
|
clinical studies
|
2020
|
scheduled
|
|
|
HOVON 150
|
clinical studies
|
2019
|
ongoing - rec...
|
|
| |
